宋坤;孔北华;

• 1:山东大学齐鲁医院妇产科

摘要(Abstract)：

<正>卵巢癌发病率居女性生殖系统恶性肿瘤第二位,病死率居首位;在女性常见肿瘤中发病率居第九位,病死率居第五位。美国预计2012年卵巢癌新发病例22 280例,死亡15 500例[1]。改善卵巢癌患者预后、提高晚期及复发患者的生活质量已成为妇科肿瘤医生面临的严重挑战。

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 宋坤;孔北华;

DOI: 10.13283/j.cnki.xdfckjz.2013.07.007

参考文献(References)：

• [1]American Cancer Society.Cancer Facts&Figures 2012[C].Atlanta:American Cancer Society,2012
• [2]Lynch HT,Lynch JF,Conway TA.Hereditary ovarian canc-er.In:Rubin SC,Sutton GP,eds.Ovarian cancer[M].NewYork:McGraw-Hill,1993:189-217
• [3]Roukos DH,Briasoulis E.Individualized preventive andtherapeutic management of hereditary breast ovarian canc-er syndrome[J].Nat Clin Pract Oncol,2007,4(10):578-90
• [4]Anderson GL,Judd HL,Kaunitz AM,et al.Effects of estro-gen plus progestin on gynecologic cancers and associateddiagnostic procedures:the Women's Health Initiative ran-domized trial[J].JAMA,2003,290(13):1739-1748
• [5]Lacey JV Jr,Mink PJ,Lubin JH,et al.Menopausal hor-mone replacement therapy and risk of ovarian cancer[J].JAMA,2002,288(3):334-341
• [6]Beral V,Million Women Study Collaborators,Bull D,et al.Ovarian cancer and hormone replacement therapy in theMillion Women Study[J].Lancet,2007,369(9574):1703-1710
• [7]Lacey JV Jr,Brinton LA,Leitzmann MF,et al.Menopausalhormone therapy and ovarian cancer risk in the NationalInstitutes of Health-AARP Diet and Health Study Cohort[J].J Natl Cancer Inst,2006,98(19):1397-1405
• [8]Hankinson SE,Hunter DJ,Colditz GA,et al.Tubal liga-tion,hysterectomy,and risk of ovarian cancer:a prospec-tive study[J].JAMA,1993,270(23):2813-2818
• [9]Parker WH,Broder MS,Chang E,et al.Ovarian conserva-tion at the time of hysterectomy and long-term health out-comes in the nurses'health study[J].Obstet Gynecol,2009,113(5):1027-1037
• [10]Finch A,Beiner M,Lubinski J,et al.Salpingo-oophorecto-my and the risk of ovarian,fallopian tube,and peritonealcancers in women with a BRCA1 or BRCA2 Mutation[J].JAMA,2006,296(2):185-192
• [11]Rebbeck TR,Lynch HT,Neuhausen SL,et al.Prophylac-tic oophorectomy in carriers of BRCA1 or BRCA2 muta-tions[J].N Engl J Med,2002,346(21):1616-1622
• [12]Domchek SM,Friebel TM,Neuhausen SL,et al.Mortalityafter bilateral salpingo-oophorectomy in BRCA1 andBRCA2 mutation carriers:a prospective cohort study[J].Lancet Oncol,2006,7(3):223-229
• [13]Kauff ND,Satagopan JM,Robson ME,et al.Risk-reducingsalpingo-oophorectomy in women with a BRCA1 orBRCA2 mutation[J].N Engl J Med,2002,346(21):1609-1615
• [14]Tworoger SS,Fairfield KM,Colditz GA,et al.Associationof oral contraceptive use,other contraceptive methods,andinfertility with ovarian cancer risk[J].Am J Epidemiol,2007,166(8):894-901
• [15]Collaborative Group on Epidemiological Studies of Ovari-an Cancer,Beral V,Doll R,et al.Ovarian cancer and oralcontraceptives:collaborative reanalysis of data from 45 ep-idemiological studies including 23257 women with ovariancancer and 87,303 controls[J].Lancet.2008,371(9609):303-314
• [16]Narod SA,Sun P,Ghadirian P,et al.Tubal ligation andrisk of ovarian cancer in carriers of BRCA1 or BRCA2mutations:a case-control study[J].Lancet,2001,357(9267):1467-1470
• [17]Menon U,Gentry-Maharaj A,Hallett R,et al.Sensitivityand specificity of multimodal and ultrasound screening forovarian cancer,and stage distribution of detected canc-ers:results of the prevalence screen of the UK Collabora-tive Trial of Ovarian Cancer Screening(UKCTOCS)[J].Lancet Oncol,2009,10(4):327-340
• [18]Buys SS,Partridge E,Black A,et al.Effect of screeningon ovarian cancer mortality:the Prostate,Lung,Colorectaland Ovarian(PLCO)Cancer Screening RandomizedControlled Trial[J].JAMA,2011,305(22):2295-2303
• [19]Moore RG,Brown AK,Miller MC,et al.The use of multi-ple novel tumor biomarkers for the detection of ovariancarcinoma in patients with a pelvic mass[J].Gynecol On-col,2008,108(2):402-408
• [20]Muller CY.Doctor,should I get this new ovarian cancertest-OVA1?[J].Obstet Gynecol,2010,116(2 Pt 1):246-247
• [21]Bristow RE,Tomacruz RS,Armstrong DK,et al.Survivaleffect of maximal cytoreductive surgery for advanced ovar-ian carcinoma during the platinum era:a meta-analysis[J].J Clin Oncol,2002,20(5):1248-1259
• [22]Vernooij F,Heintz P,Witteveen E,et al.The outcomes ofovarian cancer treatment are better when provided by gy-necologic oncologists and in specialized hospitals:a sys-tematic review[J].Gynecol Oncol,2007,105(3):801-812
• [23]Panici PB,Maggioni A,Hacker N,et al.Systematic aorticand pelvic lymphadenectomy versus resection of bulkynodes only in optimally debulked advanced ovarian canc-er:a randomized clinical trial[J].J Natl Cancer Inst,2005,97(8):560-566
• [24]Redman CW,Warwick J,Luesley DM,et al.Interventiondebulking surgery in advanced epithelial ovarian cancer[J].Br J Obstet Gynaecol,1994,101(2):142-146
• [25]van der Burg ME,van Lent M,Buyse M,et al.The effectof debulking surgery after induction chemotherapy on theprognosis in advanced epithelial ovarian cancer.Gyneco-logical Cancer Cooperative Group of the European Organi-zation for Research and Treatment of Cancer[J].N EnglJ Med,1995,332(10):629-634
• [26]Rose PG,Nerenstone S,Brady MF,et al.Secondary surgi-cal cytoreduction for advanced ovarian carcinoma[J].NEngl J Med,2004,351(24):2489-2497
• [27]Vergote I,Trope CG,Amant F,et al.NCIC Clinical TrialsGroup.Neoadjuvant chemotherapy or primary surgery instage IIIC or IV ovarian cancer[J].N Engl J Med,2010,363(10):943-953
• [28]Harter P,du Bois A,Hahmann M,et al.Surgery in recur-rent ovarian cancer:the Arbeitsgemeinschaft Gynaekolo-gische Onkologie(AGO)DESKTOP OVAR trial[J].Ann Surg Oncol,2006,13(12):1702-1710
• [29]Harter P,Sehouli J,Reuss A,et al.Prospective validationstudy of a predictive score for operability of recurrent o-varian cancer:the Multicenter Intergroup Study DESKTOPII.A project of the AGO Kommission OVAR,AGO StudyGroup,NOGGO,AGO-Austria,and MITO[J].Int J Gyne-col Cancer,2011,21(2):289-295
• [30]Bell J,Brady MF,Young RC,et al.Gynecologic OncologyGroup.Randomized phase III trial of three versus six cy-cles of adjuvant carboplatin and paclitaxel in early stageepithelial ovarian carcinoma:a Gynecologic OncologyGroup study[J].Gynecol Oncol,2006,102(3):432-439
• [31]Bookman MA,Brady MF,McGuire WP,et al.Evaluationof new platinum-based treatment regimens in advanced-stage ovarian cancer:a Phase III Trial of the GynecologicCancer Intergroup[J].J Clin Oncol,2009,27(9):1419-1425
• [32]Katsumata N,Yasuda M,Takahashi F,et al.Dose-densepaclitaxel once a week in combination with carboplatinevery 3 weeks for advanced ovarian cancer:a phase 3,open-label,randomised controlled trial[J].Lancet,2009,374(9698):1331-1338
• [33]Alberts DS,Liu PY,Hannigan EV,et al.Intraperitonealcisplatin plus intravenous cyclophosphamide versus intra-venous cisplatin plus intravenous cyclophosphamide forstage III ovarian cancer[J].N Engl J Med,1996,335(26):1950-1955
• [34]Markman M,Bundy BN,Alberts DS,Fowler JM,et al.Phase III trial of standard-dose intravenous cisplatin pluspaclitaxel versus moderately high-dose carboplatin fol-lowed by intravenous paclitaxel and intraperitoneal cispl-atin in small-volume stage III ovarian carcinoma:an in-tergroup study of the Gynecologic Oncology Group,South-western Oncology Group,and Eastern Cooperative Oncol-ogy Group[J].J Clin Oncol,2001,19(4):1001-1007
• [35]Armstrong DK,Bundy B,Wenzel L,et al.Intraperitonealcisplatin and paclitaxel in ovarian cancer[J].N Engl JMed,2006,354(1):34-43
• [36]http://ctep.cancer.gov/highlights/clin_annc_010506.pdf
• [37]Markman M,Liu PY,Moon J,et al.Impact on survival of12 versus 3 monthly cycles of paclitaxel(175 mg/m2)administered to patients with advanced ovarian cancerwho attained a complete response to primary platinum-pa-clitaxel:follow-up of a Southwest Oncology Group and Gy-necologic Oncology Group phase 3 trial[J].Gynecol On-col,2009,114(2):195-198
• [38]Pfisterer J,Weber B,Reuss A,et al.Randomized phaseIII trial of topotecan following carboplatin and paclitaxelin first-line treatment of advanced ovarian cancer:a gyne-cologic cancer intergroup trial of the AGO-OVAR and GI-NECO[J].J Natl Cancer Inst,2006,98(15):1036-1045
• [39]De Placido S,Scambia G,Di Vagno G,et al.Topotecancompared with no therapy after response to surgery andcarboplatin/paclitaxel in patients with ovarian cancer:Multicenter Italian Trials in Ovarian Cancer(MITO-1)randomized study[J].J Clin Oncol,2004,22(13):2635-2642
• [40]Pecorelli S,Favalli G,Gadducci A,et al.Phase III trial ofobservation versus six courses of paclitaxel in patientswith advanced epithelial ovarian cancer in complete re-sponse after six courses of paclitaxel/platinum-basedchemotherapy:final results of the After-6 protocol 1[J].JClin Oncol,2009,27(28):4642-4648
• [41]Parmar MK,Ledermann JA,Colombo N,et al.Paclitaxelplus platinum-based chemotherapy versus conventionalplatinum-based chemotherapy in women with relapsed o-varian cancer:the ICON4/AGO-OVAR-2.2 trial[J].Lancet,2003,361(9375):2099-2106
• [42]Pfisterer J,Plante M,Vergote I,et al.Gemcitabine pluscarboplatin compared with carboplatin in patients withplatinum-sensitive recurrent ovarian cancer:an intergrouptrial of the AGO-OVAR,the NCIC CTG,and the EORTCGCG[J].J Clin Oncol,2006,24(29):4699-4707
• [43]Pujade-lauraine E,Wagner U,Aavall-lundqvist E,et al.Pegylated liposomal doxorubicin and carboplatin com-pared with paclitaxel and carboplatin for patients withplatinum-sensitive ovarian cancer in late relapse[J].JClin Oncol,2010,28(20):3323-3329
• [44]Kaye SB,Colombo N,Monk BJ,et al.Trabectedin pluspegylated liposomal doxorubicin in relapsed ovarian canc-er delays third-line chemotherapy and prolongs the plati-num-free interval[J].Ann Oncol,2011,22(1):49-58
• [45]Poveda A,Vergote I,Tjulandin S,et al.Trabectedin pluspegylated liposomal doxorubicin in relapsed ovarian canc-er:outcomes in the partially platinum-sensitive(platinum-free interval 6-12months)subpopulation of OVA-301phase III randomized trial[J].Ann Oncol,2011,22(1):39-48
• [46]Monk BJ,Herzog TJ,Kaye SB,et al.Trabectedin plus pe-gylated liposomal doxorubicin in recurrent ovarian cancer[J].J Clin Oncol,2010,28(19):3107-3114
• [47]Ferrandina G,Ludovisi M,Lorusso D,et al.Phase III trialof gemcitabine compared with pegylated liposomal doxoru-bicin in progressive or recurrent ovarian cancer[J].J ClinOncol,2008,26(6):890-896
• [48]Gordon AN,Tonda M,Sun S,et al.Long-term survival ad-vantage for women treated with pegylated liposomal doxo-rubicin compared with topotecan in a phase 3 randomizedstudy of recurrent and refractory epithelial ovarian cancer[J].Gynecol Oncol,2004,95(1):1-8
• [49]Rustin GJ,vander Burg ME,Griffin CL,et al.Early versusdelayed treatment of relapsed ovarian cancer(MRCOV05/EORTC 55955):a randomised trial[J].Lancet,2010,376(9747):1155-1163
• [50]Perren TJ,Swart AM,Pfisterer J,et al.A phase 3 trial ofbevacizumab in ovarian cancer[J].N Engl J Med,2011,365(26):2484-2496
• [51]Burger RA,Brady MF,Bookman MA,et al.Incorporationof bevacizumab in the primary treatment of ovarian cancer[J].N Engl J Med,2011,365(26):2473-2483